冠心病合并糖尿病患者动脉粥样硬化性心血管风险的抗栓治疗
综述探讨冠心病合并糖尿病患者抗栓策略。糖尿病患者因血小板高反应性、高凝状态及内皮功能障碍而血栓风险增高。无冠心病者不常规推荐阿司匹林一级预防,因大出血风险抵消缺血获益;已确诊冠心病者二级预防可采用单联、双联抗血小板或双通路抑制,但需权衡出血风险。
要点
- 无冠心病糖尿病患者不常规推荐阿司匹林一级预防,出血风险抵消获益。
- 合并冠心病者二级预防可选单联、双联抗血小板或双通路抑制。
- 糖尿病患者抗栓绝对获益更大但出血风险更高,需排除高出血风险者。
核心结论
- 糖尿病合并冠心病患者从强化抗栓治疗中绝对获益更大,但以出血风险增加为代价,排除高出血风险者后净临床获益支持强化长期抗栓。
研究设计与样本
- 综述文章,概述冠心病合并糖尿病患者动脉粥样硬化性心血管事件一级和二级预防的当前及 evolving 抗栓策略。
主要发现
- 糖尿病患者因血小板高反应性、高凝状态和内皮功能障碍而血栓风险增高,动脉粥样硬化性心血管事件风险高于无糖尿病患者。
- 无冠心病的糖尿病患者不常规推荐阿司匹林一级预防,因大出血风险增加在很大程度上抵消其缺血获益。
- 合并冠心病的糖尿病患者二级预防抗血小板策略包括单联抗血小板(如阿司匹林或P2Y12抑制剂)、双联抗血小板(如阿司匹林联合P2Y12抑制剂)和双通路抑制(如阿司匹林联合血管剂量直接口服抗凝药利伐沙班)。
- 排除高出血风险个体后,研究显示净临床获益支持糖尿病合并冠心病患者使用强化长期抗栓治疗。
临床怎么用
- 对无冠心病的糖尿病患者,不常规使用阿司匹林进行一级预防。
- 对合并冠心病的糖尿病患者,根据缺血和出血风险选择单联、双联抗血小板或双通路抑制进行二级预防。
- 强化抗栓治疗前应评估并排除高出血风险个体,以最大化净临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status, and endothelial dysfunction. As such, they are more prone to atherosclerotic cardiovascular events than patients without DM, both before and after coronary artery disease (CAD) is established. In patients with DM without established CAD, primary prevention with aspirin is not routinely advocated because of its increased risk of major bleeding that largely offsets its ischemic benefit. In patients with DM with established CAD, secondary prevention with antiplatelet drugs is an asset of pharmacological strategies aimed at reducing the risk of atherosclerotic cardiovascular events and their adverse prognostic consequences. Such antithrombotic strategies include single antiplatelet therapy (eg, with aspirin or a P2Y12 inhibitor), dual antiplatelet therapy (eg, aspirin combined with a P2Y12 inhibitor), and dual-pathway inhibition (eg, aspirin combined with the vascular dose of the direct oral anticoagulant rivaroxaban) for patients with chronic ischemic heart disease, acute coronary syndromes, and those undergoing percutaneous coronary intervention. Because of their increased risk of thrombotic complications, patients with DM commonly achieve enhanced absolute benefit from more potent antithrombotic approaches compared with those without DM, which most often occurs at the expense of increased bleeding. Nevertheless, studies have shown that when excluding individuals at high risk for bleeding, the net clinical benefit favors the use of intensified long-term antithrombotic therapy in patients with DM and CAD. Several studies are ongoing to establish the role of novel antithrombotic strategies and drug formulations in maximizing the net benefit of antithrombotic therapy for patients with DM. The scope of this review article is to provide an overview of current and evolving antithrombotic strategies for primary and secondary prevention of atherosclerotic cardiovascular events in patients with CAD and DM.
引用
- Capodanno D, Angiolillo DJ. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation. 2020. PMID: 33253005. doi:10.1161/CIRCULATIONAHA.120.045465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。